A Phase I-II Study of Sorafenib (Nexavar) in Combination With Capecitabine and Cisplatin (XP) in Patients With Advanced Gastric Cancer

Trial Profile

A Phase I-II Study of Sorafenib (Nexavar) in Combination With Capecitabine and Cisplatin (XP) in Patients With Advanced Gastric Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Sorafenib (Primary) ; Capecitabine; Cisplatin
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2010 Primary endpoints identified, actual patient number (21) added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top